Michael J. Maschio

92 Cottonwood Crescent
Cambridge, ON, Canada

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 21 publications

The cost-effectiveness of vaccination against COVID-19 in at-risk populations and older adults in the United Kingdom: Projections using a dynamic transmission model.

The cost-effectiveness of vaccination against COVID-19 in at-risk populations and older adults in the United Kingdom: Projections using a dynamic transmission model.

Journal: Vaccine
Published: February 17, 2026

Substantial reduction in the clinical and economic burden of disease following variant-adapted mRNA COVID-19 vaccines in immunocompromised patients in France.

Substantial reduction in the clinical and economic burden of disease following variant-adapted mRNA COVID-19 vaccines in immunocompromised patients in France.

Journal: Human vaccines & immunotherapeutics
Published: November 14, 2024

The potential clinical impact and cost-effectiveness of the updated COVID-19 mRNA Autumn 2024 vaccines in the United Kingdom.

The potential clinical impact and cost-effectiveness of the updated COVID-19 mRNA Autumn 2024 vaccines in the United Kingdom.

Journal: Journal of medical economics
Published: October 31, 2024

The Potential Economic Impact of the Updated COVID-19 mRNA Fall 2023 Vaccines in Japan.

The Potential Economic Impact of the Updated COVID-19 mRNA Fall 2023 Vaccines in Japan.

Journal: Vaccines
Published: January 16, 2024

Clinical impact and cost-effectiveness of the updated COVID-19 mRNA Autumn 2023 vaccines in Germany.

Clinical impact and cost-effectiveness of the updated COVID-19 mRNA Autumn 2023 vaccines in Germany.

Journal: Journal of medical economics
Published: December 05, 2023

Projections of the incidence of COVID-19 in Japan and the potential impact of a Fall 2023 COVID-19 vaccine.

Projections of the incidence of COVID-19 in Japan and the potential impact of a Fall 2023 COVID-19 vaccine.

Journal: Vaccine
Published: November 20, 2023

The potential clinical impact and cost-effectiveness of the updated COVID-19 mRNA fall 2023 vaccines in the United States.

The potential clinical impact and cost-effectiveness of the updated COVID-19 mRNA fall 2023 vaccines in the United States.

Journal: Journal of medical economics
Published: November 14, 2023

The potential clinical impact of implementing different COVID-19 boosters in fall 2022 in the United States.

The potential clinical impact of implementing different COVID-19 boosters in fall 2022 in the United States.

Journal: Journal of medical economics
Published: October 03, 2022

The Cost-Effectiveness of Vaccination of Older Adults with an MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared to Other Available Quadrivalent Vaccines in Germany.

The Cost-Effectiveness of Vaccination of Older Adults with an MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared to Other Available Quadrivalent Vaccines in Germany.

Journal: Vaccines
Published: June 24, 2022

An Economic Comparison of Influenza Vaccines Recommended for Use in Eligible Adults under 65 Years in the United Kingdom.

An Economic Comparison of Influenza Vaccines Recommended for Use in Eligible Adults under 65 Years in the United Kingdom.

Journal: Vaccines
Published: February 23, 2022

The cost-effectiveness of an adjuvanted quadrivalent influenza vaccine in the United Kingdom.

The cost-effectiveness of an adjuvanted quadrivalent influenza vaccine in the United Kingdom.

Journal: Human vaccines & immunotherapeutics
Published: September 22, 2021

The Cost-Effectiveness of Expanding Vaccination with a Cell-Based Influenza Vaccine to Low Risk Adults Aged 50 to 64 Years in the United Kingdom.

The Cost-Effectiveness of Expanding Vaccination with a Cell-Based Influenza Vaccine to Low Risk Adults Aged 50 to 64 Years in the United Kingdom.

Journal: Vaccines
Published: April 23, 2021
Showing 1-12 of 21

Last Updated: 09/26/2026